News
We send the latest information from SMC Laboratories.
New Service: In Vitro Assay for Fibrosis Evaluation
We are delighted to announce the launch of our new in vitro assay service for fibrosis evaluation. By launching this service, we now offer a cost-effective and efficient way to conduct preliminary studies and screen compounds for potential fibrotic effects, saving valuable time and resources in your drug development journey. This not only speeds…
Introducing our new pulmonary fibrosis model: Silica-induced pulmonary fibrosis model
Today, we are pleased to announce that we have expanded our preclinical model lineup by including the “Silica-induced pulmonary fibrosis model”. Pulmonary fibrosis in silica models occurs early and is maintained long term. Hence, this model is one of the most beneficial model mice for therapeutic study for pulmonary fibrosis. In general, human pulmonary…
Study published in Pharmacol Res Perspect. on the efficacy of the inhibitor of serine palmitoyltransferase (SPT) in STAM™
SMC is proud to announce that Chugai Pharmaceutical Co., Ltd. (JPN) has published the results of their study using our pre-clinical services with the STAM™ mouse in Pharmacol Res Perspect. Title Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non‐alcoholic steatohepatitis (NASH) (Hada et…
Introduction of Inflammatory Bowel Disease mouse model
Today, we give you a brief introduction to the dextran sulfate sodium (DSS) -induced colitis model, which is a clinically representative mouse model that can be used to conduct drug efficacy studies targeting Inflammatory Bowel Disease. This model is widely used to elucidate the mechanism of IBD pathogenesis and evaluate drug candidates because of…
Study published in Int. J. Mol. Sci. on the efficacy of Mesenchymal stromal cell/stem cell small extracellular vesicles (MSC-sEV) in STAM™
SMC is proud to announce that Agency for Science, Technology and Research (A*STAR) (SGP) has published the results of their study using our pre-clinical services with the STAM™ model in Int. J. Mol. Sci. Title MSC−sEV Treatment Polarizes Pro−Fibrotic M2 Macrophages without Exacerbating Liver Fibrosis in NASH (Zhang et al., Int J Mol Sci.,…
Announcement of webinar 【HOW NAFLD ACTIVITY SCORE IS SCORED IN NON-CLINICAL STUDIES】
Today we are excited to invite you to join our Online Linkedin Webinar that will be taking place on May 18th (JST) from 9:30 AM. In this webinar, we will introduce STAM™ mice and give a lecture on the NAFLD activity score scoring method recommended by the FDA as the primary endpoint of clinical…
The STAM™ mouse model: a clinically relevant, spontaneous HCC model
We would like to introduce a study published by our client using our STAM™ mouse model (Dow, et al. Proc Natl Acad Sci U S A. 2018). Title: Integrative genomic analysis of mouse and human hepatocellular carcinoma Dow, et al. Proc Natl Acad Sci U S A. 2018 The STAM™ model is…
Introduction of chronic kidney disease mice models
I am writing you today to share some information on our Chronic kidney disease (CKD) models. CKD is a condition that is characterized by abnormalities in the structure or function of the kidneys. It is a global public health problem and causes a rising incidence and prevalence of kidney failure with poor outcomes. However,…
SMC attend Digital partnering events!
We are pleased to announce that SMC Laboratories will be virtually attending the following digital events in May 2023. We would love to have the opportunity to meet with you virtually and introduce ourselves and our preclinical models, so please join us! If you would like to discuss specific collaboration opportunities, please send us…
Introduction of NASH model with high clinical correlation
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Around the world, the prevalence of NAFLD has now increased to 30%, and it is expected to continue to increase [Younossi Z et al., Hepatology. 2023]. One of the risks of NAFLD is its ability to progress to other…